北京商报讯（记者 丁宁）11月21日晚间，人民同泰（600829）发布公告称，公司股票于11月19日—21 日连续3个交易日内日收盘价格跌幅偏离值累计达到20%，属于《上海证券交易所交易规则》规定的股 票交易异常波动情形。 值得一提的是，公司于11月20日披露了《控股股东减持股份计划公告》，公司控股股东哈药股份计划通 过集中竞价交易方式减持公司股份，拟减持股份数量不超过579.88万股，占公司总股本的比例不超过 1%。 人民同泰表示，经公司自查，并向公司控股股东哈药股份、间接控股股东哈药集团有限公司询证，不存 在应披露而未披露的重大事项或重要信息。 ...

Core Points - The stock of Renmin Tongtai (600829) experienced a limit down today, with a turnover rate of 3.80% and a trading volume of 285 million yuan, reflecting a price fluctuation of 2.40% [2] - The stock was listed on the Shanghai Stock Exchange's watch list due to a daily price deviation of -7.58%, with a net selling amount of 7.56 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 43 million yuan, with a buying amount of 17.72 million yuan and a selling amount of 25.28 million yuan, resulting in a net selling of 7.56 million yuan [2] - Over the past six months, the stock has appeared on the watch list 12 times, with an average price drop of 0.80% the next day and an average decline of 0.67% over the following five days [2] - The stock saw a net outflow of 17.55 million yuan in major funds today, with a significant outflow of 2.63 million yuan from large orders and 14.92 million yuan from major funds [2] - In the past five days, the net outflow of major funds reached 686 million yuan [2] - The company's Q3 report released on October 21 indicated a total revenue of 7.846 billion yuan for the first three quarters, representing a year-on-year growth of 2.19%, while net profit was 112 million yuan, down 45.69% year-on-year [2]

证券代码：600829 证券简称：人民同泰 编号：临 2025-036 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 哈药集团人民同泰医药股份有限公司（以下简称"公司"）股 票于 2025 年 11 月 19 日、2025 年 11 月 20 日、2025 年 11 月 21 日连 续 3 个交易日内日收盘价格跌幅偏离值累计达到 20%，属于《上海证 券交易所交易规则》规定的股票交易异常波动情形。 经公司自查，并向公司控股股东哈药集团股份有限公司(以下 简称"哈药股份")、间接控股股东哈药集团有限公司询证，不存在 应披露而未披露的重大事项或重要信息。 公司于 2025 年 11 月 20 日披露了《控股股东减持股份计划公 告》，公司控股股东哈药股份计划于 2025 年 12 月 11 日至 2026 年 3 月 10 日期间，通过集中竞价交易方式减持公司股份，拟减持股份数 量不超过 5,798,800 股，占公司总股本的比例不超过 1%。 敬请广大投资者 ...

证券之星消息，11月21日医药商业板块较上一交易日下跌3.02%，人民同泰领跌。当日上证指数报收于 3834.89，下跌2.45%。深证成指报收于12538.07，下跌3.41%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603108 润达医疗 | | 2559.97万 | 8.07% | -1214.50万 | -3.83% | -1345.46万 | -4.24% | | 603939 | 益丰药房 | 1822.52万 | 11.15% | -551.21万 | -3.37% | -1271.31万 | -7.78% | | 600538 | 国发股份 | 589.73万 | 7.26% | 195.71万 | 2.41% | -785.44万 | -9.67% | | 301584 建发致新 | | 379.05万 | 0.97% | 2174.48万 | 5.55% | ...

Market Overview - Major market indices opened lower, with the Shanghai Composite Index down 0.87% at 3896.66 points, the Shenzhen Component Index down 1.76% at 12752.72 points, and the ChiNext Index down 2.07% at 2979.37 points [1] Stock Performance - A total of 357 stocks rose at the opening, with newly listed stock N Dapeng surging 289.89% [1] - There were 4 stocks hitting the daily limit up, including *ST Mubang with 5 consecutive limit ups, Yingli Automotive with 4 limit ups in 6 days, and Meng Tian Home with 3 consecutive limit ups [1] - Conversely, 4869 stocks declined at the opening, with 23 stocks hitting the daily limit down, including Renmin Tongtai and Dazhong Mining [1] Price Continuity - Among the stocks that hit the limit up yesterday, 4 stocks continued to hit the limit up today, including Yingli Automotive and Shen Zhonghua A [1] - Stocks that opened lower included Intelligent Control, Jiumuwang, and Dawi Shares, with opening declines of 10.00%, 9.99%, and 9.99% respectively [1] - From the stocks that hit the limit down yesterday, 7 stocks continued to hit the limit down today, including Renmin Tongtai and *ST Yunwang [1]

证券日报网讯人民同泰（600829）11月20日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东总数为27，745户。 ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.51% on November 20, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 26.18, up 10.00% [1] - KaiKai Industry (600272) at 14.58, up 4.14% [1] - Zhejiang Zhenyuan (000705) at 9.91, up 1.64% [1] - Major decliners included: - Renmin Tongtai (600829) at 14.36, down 9.97% [2] - Jianfa Zhixin (301584) at 32.34, down 4.88% [2] - Shuyupingmin (301017) at 13.40, down 3.11% [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 260 million yuan from institutional investors, while retail investors had a net inflow of 264 million yuan [2] - The overall capital flow indicates a shift in investor sentiment, with retail investors showing more interest in the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 36.98 million yuan from institutional investors, but a net outflow from retail investors [3] - KaiKai Industry (600272) also saw a net inflow from institutional investors of 27.76 million yuan, with retail investors showing a net outflow [3] - Other stocks like Zhejiang Zhenyuan (000705) and Dajia Weikang (301126) experienced mixed capital flows, indicating varied investor interest [3]

Group 1: New Stock Offerings - Tianpu Co., Ltd. (Stock Code: 605255) has a tender offer period from November 20, 2025, to December 19, 2025[1] - Hangzhou Steam Turbine Co., Ltd. (Stock Code: 200771) has a cash option declaration period from November 19, 2025, to November 25, 2025[1] - Central Plaza (Stock Code: 600280) announced on November 20, 2025[1] Group 2: Stock Performance Alerts - Moen Electric (Stock Code: 002451) reported severe abnormal fluctuations on November 14, 2025[1] - ST Yuancheng (Stock Code: 603388) reported severe abnormal fluctuations on November 11, 2025[1] - ST Keli Da (Stock Code: 603828) reported severe abnormal fluctuations on November 12, 2025[1] Group 3: Recent Announcements - Jiumuwang (Stock Code: 601566) announced on November 20, 2025[1] - Taiping Bird (Stock Code: 603877) announced on November 20, 2025[1] - Huaci Co., Ltd. (Stock Code: 001216) announced on November 20, 2025[1]

格隆汇11月20日｜人民同泰(600829.SH)早盘一度跌停，现跌9.72%报14.4元，总市值83.5亿元；此前11月10日至17日，该股录得6连板涨停。人民同泰公告 称，控股股东哈药集团股份有限公司持有公司股份433,894,354股，占公司总股本的74.82%，因经营需要，计划自公告披露之日起15个交易日后的3个月内， 通过集中竞价交易方式减持不超过579.88万股的公司股份，占公司总股本比例不超过1%。减持期间为2025年12月11日至2026年3月10日。(格隆汇) ...